Many Huntington disease (HD) mutation carriers already have cognitive and psychiatric
symptoms in the premanifest (premotor) phase of the disease (pre-HD), but the molecular …

The type 1 cannabinoid receptor (CB1) is a crucial modulator of synaptic transmission in the
brain. Animal and postmortem human data suggest that mutant huntingtin represses CB1 …

Background: Neuropsychiatric disturbances are common in Huntington's Disease (HD) and
have been observed in gene-positive individuals several years prior to the onset of motor …

Huntington's disease (HD) is an inherited neurodegenerative disease characterised by cell
dysfunction and death in the basal ganglia and cortex. Currently there are no effective …

Several lines of evidence imply early alterations in metabolic and endocannabinoid
neurotransmission in Huntington disease (HD). Using [18 F] MK-9470 and small animal …

Neuropsychological and neuroimaging changes have been observed in individuals with the
Huntington's disease (HD) gene expansion prior to the onset of manifest HD. This cross …

Phenotypic manifestations of Huntington disease (HD) can be detected at least 15 years
prior to the time when a motor diagnosis is given. Advances in clinical care and future …

Background and purpose: Functional neuroimaging studies have suggested a dysfunction of
prefrontal regions in clinically pre‐symptomatic individuals with the Huntington's disease …

Evidence from magnetic resonance imaging (MRI) suggests early structural and functional
brain changes in individuals with the Huntington's disease (HD) gene mutation who are …

Huntington's disease (HD) is a progressive neurodegenerative genetic disorder which leads
to motor, cognitive and psychiatric disturbances. The primary neuropathological hallmark is …